Introduction
The development of target-based drug discovery has provided novel approaches for the treatment of malignancies. However, despite the advances in drug discovery it is clear that rationally designed chemotherapeutics such as the BCR-ABL kinase inhibitor Gleevec, although effective, do not circumvent the emergence of clinical drug resistance (Hochhaus et al., 2001; Sawyers, 2001; Blagosklonny, 2002) . Recent observations continue to support the importance of identifying and targeting drug-resistant mechanism(s) as a viable strategy for improving the efficacy of cancer chemotherapy. A cancer cell can employ multiple strategies that ultimately favor survival following cytotoxic insult. These mechanisms include decreased drug uptake, increased drug efflux, alterations in the drug target, drug metabolism, repair of DNA damage, cell cycle checkpoint mediators, and changes in downstream mediators of the apoptotic pathway (Dalton and Salmon, 1992; Gottesman et al., 2002) (Figure 1) .
Traditionally, drug resistance mechanisms have been identified and functionally characterized in unicellular models. Implicit in these unicellular models is the lack of consideration of host-tumor cell interactions that may participate in the emergence of the drug-resistant phenotype. We propose that the initial selection pressure for tumor growth and survival is represented by hosttumor cell interactions and furthermore, these same interactions may participate in modulating drug response and emergence of a stable drug resistance. Experimental data supporting this concept were provided by Teicher et al. (1990) . These investigators showed that treatment of mice bearing EMT-6 mammary tumors over a 6-month period with either cis-platinum, carboplatin, cyclophosphamide or thiopetia resulted in the selection of a drug resistance phenotype that was operative in vivo. Conversely, the resistance phenotype was not detected in a unicellular tissue culture system, indicating the importance of the microenvironment in mediating the expression of a functional drug resistance phenotype. Thus we suggest that in order to identify clinically relevant drug-resistant targets, new models must be developed allowing for reconstitution of host-tumor cell interactions. The focus of this review is the development of one such model, namely cell adhesion-mediated drug resistance (CAM-DR) as a model to investigate survival pathways that participate in de novo drug resistance and eventually allow for classical drug resistance mechanisms to be acquired.
Tumor microenvironment
The tumor microenvironment consists of a diverse milieu of cytokines, growth factors, hormones and components of the extracellular matrix. Activation of some growth and cytokine receptors favors the progression and survival of tumors, and several soluble factors have been implicated in negatively regulating drug response including vascular endothelial growth factor (VEGF) (Dias et al., 2002; Tran et al., 2002) , nitric oxide (NO) (Xu et al., 2000) and tumor growth factor beta (TGF-b) (Teicher et al., 1997; Ohmori and Price, 1998) (Figure 2 ). However, it must be noted that the inhibition of known cell survival pathways initiated by external factors may not always reverse the drug-resistant phenotype. For example, Catlett-Falcone et al. (1999) showed that activation of the IL-6 receptor in myeloma cell lines resulted in the activation of the Jak2-Stat3 pathway and increased expression of Bcl-X L . Overexpression of Bcl-X L has been associated with drug resistance in cancers (Simonian et al., 1997) . Inhibition of this pathway with the Jak2 kinase inhibitor, AG490, reduced Bcl-X L expression and sensitized cells to Fasmediated cell death. Although ectopic overexpression of Bcl-xL contributes to drug resistance, inhibition of the Jak2 signal transduction pathway by AG490 actually conferred greater resistance to topoisomerase II inhibitors (Oshiro et al., 2001) . This enhanced resistance correlated with a G1 cell cycle arrest, indicating that inhibition of signaling pathways may result in a paradoxical response due to the multivariate influence of signaling pathways on cell growth and survival pathways.
In addition to cytokines and growth factors, tumorhost interactions include cell-cell and cell matrix communication. Adhesion receptors belong to several molecular families including integrins, cadherins, selectins, syndecans and the immunoglobulin superfamily of cell adhesion molecules. The integrin family of adhesion molecules is currently the most well-documented family for its role in growth, differentiation and survival (Bohnsack and Chang, 1994; Wang et al., 1998;  Potocnik et al., 2000) . Integrin receptors are heterodimers, composed of one a and b subunit. To date, 17 a and eight b subunits have been identified and comprise 22 distinct receptors (Kumar, 1998) . Several investigators, including our own laboratory (see Table 1 ), have shown that integrin-mediated adhesion of tumor cell lines causes resistance to mechanistically distinct cytotoxic agents (Damiano et al., 1999 (Damiano et al., , 2001 Sethi et al., 1999; Damiano and Dalton, 2000; Hazlehurst et al., 2000 ).
Mechanism(s) associated with this observation will be discussed in this review.
CAM-DR models
The first model demonstrating the survival effects of cell adhesion was developed by Durand and Sutherland, (1972) . In this model, they demonstrated that forcing V79 Chinese hamster cells to grow in a spheroid culture was causative for radiation resistance relative to cells treated as a monolayer. Several techniques exist for forcing spheroid growth including coating the tissue culture flask with agar or another substrate such as polyHEMA or in a spinner flask that is continually rotated. The end result is that the adhesive force for cellcell interactions is greater than the affinity for the substrate forcing homotypic cell aggregation. This model more closely resembles the architecture of a solid tumor in vivo. The implication of the spheroid model is that cell-cell contact enhances the survival of tumor cells in response to cytotoxic stimuli. A multitude of homotypic adhesion molecules may mediate resistance in a spheroid model. In fact, glycoproteins such as hyaluronic acid as well as E-cadherins have been implicated in mediating spheroid drug resistance (St Croix et al., 1998a, b) . However, elucidating the signal transduction pathways contributing to drug resistance will be problematic without the ability to investigate the activation of specific adhesion receptors.
Our laboratory developed a model to investigate adhesion of hematopoietic cell lineages to one specific component of the extracellular matrix, fibronectin (FN) (Damiano et al., 1999) . Our initial observations using this model of cell adhesion-mediated drug resistance (CAM-DR) was demonstrated in myeloma cell lines. Myeloma is a disease characterized by the latent accumulation of plasma cells with a relatively low growth index. Myeloma tumor cells home to the bone marrow suggesting that this specific microenvironment may be critical for the survival, progression and perhaps intrinsic resistance to chemotherapy associated with this disease. The bone marrow microenvironment is considered a rich source of extracellular matrixes, and myeloma cell lines typically express the b1 integrins VLA-4 (a4b1) and VLA-5 (a5b1) (Jensen et al., 1993; Cook et al., 1996; Damiano et al., 1999) . Further rationale for initially investigating b1 integrins was provided by previous reports indicating that adhesion of hematopoietic lineages via a4b1 integrin blocks apop- 
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Resistance of microenvironment to drugs LA Hazlehurst et al tosis (Koopman et al., 1994; Wang et al., 1998) . Thus, we proposed that because the bone marrow microenvironment is rich in components of the extracellular matrix and b1 integrin activation was shown to favor cell survival, that adhesion via b1 integirns may protect myeloma cells from drug-induced apoptosis. Indeed, Damiano et al. (1999) showed that adhesion of myeloma cell lines to fibronectin via b1 integrins conferred resistance to the chemotherapeutic agents doxorubicin and melphalan. Multiple myeloma is not the only hematopoietic malignancy in which CAM-DR may contribute to disease progression. It is well accepted that the initial chemotherapy of CML and AML results in rapid clearing of detectable disease in the peripheral blood. However, elimination of disease in the bone marrow is a more arduous task, suggesting that de novo drug resistance associated with the bone marrow microenvironment may contribute to residual disease. Consistent with these clinical observations we have shown a similar CAM-DR phenotype in CML and AML cell lines, indicating that adhesion-mediated drug resistance may impact several malignancies (Damiano et al., 2001; ) (see Table 1 ).
An added complexity of the CAM-DR model is that several independent factors need to be considered that would be predicted to occur in vivo. For example, Taylor et al. (2000) investigated the response of B-lymphoma cells to drug treatment in the context of IL-4, CD40 and VLA-4 ligation. These investigators postulated that activation of these independent factors more closely resembles the microenvironment of the germinal center and must be considered when investigating de novo drug resistance associated with B-cell lymphoma. Their results indicated that the combination of these extracellular factors provided increased protection from etoposide-induced cell death. Moreover, they demonstrated that IL-4 cooperates with CD40 ligation to enhance BCl-xl expression and IL-4 and VCAM-1 worked in concert to inhibit etoposide-induced release of Bax from Bcl-2 binding. These observations correlated with increased protection from etoposideinduced cell death. Interestingly, it has also been shown that overexpression of either Bcl-2 or Bcl-X L in B-cell lines reduces apoptosis and results in a significant increase in radiation-induced TK1 mutations (Cherbonnel-Lasserre et al., 1996) . Collectively, these data suggest that increased survival following DNA damage may contribute to the genetic instability and emergence of acquired genetic drug resistance mechanisms.
Another model, which perhaps more closely resembles the tumor microenvironment, is to consider the response of tumor cells to chemotherapy in a bone marrow stroma model. Fortney et al. (2001) showed that coculture of B lineage tumor cells with bone marrow stroma resulted in reduced apoptosis induced by etoposide and Ara-C. Although the exact mechanism has not been fully elucidated, the CAM-DR phenotype correlated with reduced activation of caspase 3, suggesting inhibition of the apoptotic pathway. In this stroma model, cytoprotection required direct cell-cell contact, as drug resistance could not be conferred by the addition of stromal cell-conditioned media. The drug-resistant phenotype could be reversed by an anti-VCAM-1 antibody, suggesting that the VCAM-1 receptor VLA-4 is conferring resistance in this stroma model. Our laboratory has obtained similar results using multiple myeloma cell lines (Nefedova and Dalton, 2001 ). However, in our model system, the coincubation of myeloma cells with the bottom stromal layer cells allowed for increased survival of myeloma cells, which were incubated on the top layer of a transwell membrane. This soluble cytoprotection effect could not be conferred by conditioned supernatant obtained from a stromal cell culture only, indicating that production of antiapoptotic soluble factors occurs only when myleoma cells are in direct contact with the stromal layer. Understanding and elucidating the biology of the tumor microenvironment of each specific tumor type will be critical for developing models that will aid in the identification of novel targets directed at the reversal of de novo drug resistance.
Effects of adhesion on drug-induced DNA damage
Many currently used cytotoxics target DNA; our laboratory, as well as others, have investigated the effects of adhesion on DNA damage. Using topoisomerase II inhibitors, we showed, in the human myelocytic U937 and the multiple myeloma cell line RPMI 8226, that the CAM-DR phenotype correlated with decreased drug-induced DNA double-strand breaks as measured by the neutral comet assay . Furthermore, in the U937 cell line the decrease in DNA damage was associated with changes in the nuclear pools of topoisomerase II as measured by a reduction in salt extractable topoisomerase IIb. Presumably, fibronectin adhesion reduced the availability of topo IIb for forming drug-induced cleavable complexes. Similarly, Hoyt et al. (1996) also demonstrated that activation of b1 integrins in tumor derived endothelial cells or lung endothelial cells resulted in a decrease in etoposide-and bleomycininduced DNA damage (Jones et al., 2001) . Moreover, in the cell spheroid model resistance associated with topoisomerase II inhibitors also correlated with a decrease in DNA damage compared to cells grown as a monolayer (Oloumi et al., 2000) . In this model, reduction in DNA damage correlated with hypophosphorylation of topoisomerase IIa and a decrease in the nuclear cytoplasmic ratio of topoisomerase IIa. It must be noted, however, that the effect of adhesion on topoisomerase II-mediated DNA damage may be cell context specific. For example, Sethi et al. (1999) showed that adhesion via b1 integrins protected against etoposide-and doxorubicin-induced apoptosis. However, in their model system consisting of small cell lung cancer cell lines, nuclear topoisomerase II activity was not altered in spite of reduced drug activity. Our laboratory also demonstrated that cell adhesion of hematopoietic cell lines confers resistance to agents that do not depend on topoisomerase II for mediating DNA damage, such as melphalan, Ara-C and radiation (Damiano et al., 2001) .
Adhesion-mediated effects on apoptosis
Apoptosis is defined as the active process of committing cell suicide. Diverse stimuli can induce apoptosis and loss of cell anchorage is one of these mechanisms. The term for apoptosis related to loss of adhesion is called 'anoikis' for the Greek word homelessness (Frisch and Francis, 1994) . The initiating event of anoikis is not clearly defined. In some cell models Bcl-2 or Bcl-xl can inhibit detachment-induced apoptosis or anokois, suggesting a mitochondria-dependent mechanism (Rytomaa et al., 1999; Coll et al., 2002; Tiberio et al., 2002) . Another recent mechanism associated with aniokis is the release of the Bcl-2 family member Bmf from cytoskeletal elements (Puthalakath et al., 2001) . Recently two BH3 only proapoptotic BCL-2 family members, Bim and Bmf, have been shown to be sequestered by components of the cytoskeletal in healthy cells (Puthalakath et al., 1999; . Treatment of MCF7 cells with cytochalasin, detachment of cells or UV exposure all represent stimuli shown to release Bmf from actin/myosinassociated dyein light chain-2, allowing for the functional binding to Mcl-1 and Bcl-2.
In contrast to cells of epithelial origin, anoikis is not sufficient in hematopoietic lineages to cause apoptosis. However, cell attachment to components of the extracellular matrix provides additional protection from apoptotic stimuli, indicating that even in hematopoietic cell lineages adhesion favors cell survival. Shain et al. (2002) recently showed that integrin-mediated adhesion inhibits Fas-mediated apoptosis in hematopoietic tumor cell lines. This inhibition correlated with an increase in the cytosolic solubility of c-Flip L . C-Flip L shares significant protein homology with procaspase 8, with two essential conserved histidine and cysteine residues being replaced with arginine and tyrosine, respectively. Functionally, c-Flip L acts as a dominant negative with respect to the formation of a catalytically active DISC complex containing procaspase 8 Inohara et al., 1997) . Following cellular adhesion of hematopoietic cells lines to fibronectin, c-FLIP L was released from a Triton X insoluble fraction to a soluble fraction. This results in an increase in the functional binding of C-Flip L to FADD, another integral component of the DISC complex, and inhibits Fas-induced apoptosis. These data indicate that cellular adhesion protects cells not only from cytotoxic agents that initiate cell death via DNA damage but also against physiological mediators of cell death such as Fas.
Effects of cell adhesion on cell growth
Integrin-mediated adhesion of adherent cell lines typically results in increased proliferation and facilitation of cell cycle progression (Wary et al., 1996) . In contrast, we and others have shown that adhesion via b1 integrins of hematopoietic cell lines results in the inhibition of cell cycle progression (Hamdan and Luikart, 1992; Lundell et al., 1996; Hurley et al., 1997; Hazlehurst et al., 2000; Jiang et al., 2000) . Jiang et al. (2000) recently showed that adhesion of normal CD34 þ cells to FN resulted in the inhibition of DNA synthesis, which correlated with increased p27kip1 levels and the inhibition of CDK2 kinase activity. This FN-mediated inhibition of cell cycle progression could be reversed with the addition of high concentrations of IL-3 or SCF, which correlated with the suppression of FN-mediated increases in p27kip1 levels. Hazlehurst et al. (2000) reported a similar finding with the RPMI 8226 myeloma cell line. We reported that adhesion to FN of the RPMI 8226 cell line caused a reversible G1 arrest, which correlated with increased p27kip1 levels. Myeloma is characterized as a slow growing malignancy and perhaps the bone marrow microenvironment participates in the regulated growth of the disease. Moreover, similar to the spheroid model (St Croix et al., 1996) , we showed that adhesionmediated increases in p27kip1 levels were causative for the CAM-DR phenotype as reducing the p27kip1 levels with antisense partially reversed the phenotype.
Integrin signaling
To date our laboratory has identified three targets modified by cellular adhesion, topoisomerase II, p27kip1 and c-Flip L, and these targets may participate in the CAM-DR phenotype (Hazlehurst et al., 2000 ; Shain et al., 2002) . What is currently unclear is whether the post-transcriptional regulation of these targets is controlled by the same or divergent adhesion-dependent pathways. Integrin signaling is complex and it is more accurately represented as a network rather than a linear signaling pathway. Integrins do not have intrinsic kinase activity, yet following cellular adhesions one of the earliest events measured is an increase in the activation of tyrosine kinases. Experimental evidence has shown conclusively that integrin ligation, in the presence of integrin clustering, results in the recruitment of structural and signaling molecules to the focal adhesion contact (reviewed in Parsons et al., 2000) . One of the first molecules identified in this complex was the prolinerich protein focal adhesion kinase (FAK) (Hanks et al., 1992) . FAK is considered a key molecule in the recruitment of secondary signaling and structural proteins, including Src-family protein tyrosine kinses (Schaller et al., 1994) , p130Cas (Harte et al., 1996) , Shc, Grb2 (Schlaepfer et al., 1994) , PI3-3 kinase and paxillin (Hildebrand et al., 1995) . It must be noted that B cells have been reported to lack FAK. However, the related adhesion focal tyrosine kinase (RAFTK/PYK2), an FAK member homologue, is activated by integrin ligation in these cell lines and may serve a similar function as FAK in lineages lacking FAK expression (Astier et al., 1997a, b; Sieg et al., 1998) . The direct downstream targets of integrin activation that have been implicated in mediating an antiapoptotic phenotype include the activation of targets such as AKT (Lee and Juliano, 2000) , ERK (Lin et al., 1997) and JNK (Almeida et al., 2000) . For adherent cell lines, the CAM-DR phenotype has been correlated with integrinmediated signaling. For example, Sethi et al. (1999) showed using small cell lung cancer cell lines that cellular adhesion to either fibronectin, laminin or collagen IV protected from cell death induced by topoisomerase II inhibitors, cyclophosphamide and cis-platinum, and the cytoprotection could be reversed by the tyrosine phosphorylation inhibitor Tyrphostin-25. In a second study, Aoudjit and Vuori (2001) demonstrated that adhesion of breast cancer cells to fibronectin, collagen I or laminin resulted in resistance to the microtubule inhibitor paclitaxel, which correlated with a twofold increase in AKT activation. Furthermore, treatment of cells with the PI-3 kinase inhibitor LY294002 or ectopic expression of a dominant negative PI-3 kinase reversed the CAM-DR phenotype. However, one cautionary note is that blocking intracellular signaling pathways may also alter the avidity or insideout activation of integrin receptors and thus the effect of blocking these pathways on cell adhesion must also be considered before concluding that specific signal transduction pathways represent downstream targets of CAM-DR.
Many integrin-initiated signal transduction pathways converge with cytokine receptor pathways. In addition, the complexity of integrin signal transduction is further complicated by concurrent changes in cytoskeletal structure, and may affect both trafficking and recruitment of downstream signaling events. Finally, another dimension of complexity with integrin signaling is the crosstalk between cytokine receptors. For example, in breast epithelial cells, adhesion via a6b1 in the presence of insulin resulted in increased phosphorylation of the insulin receptor and of protein kinase B (Farrelly et al., 1999) . Another example of integrin crosstalk includes the IL-1 receptor, where stimulation of the receptor results in the transient recruitment of interleukin 1 receptor-associated kinase (IRAK) into focal adhesion contacts, an event required for the IL-1-dependent activation of Erk (MacGillivray et al., 2000) . The challenge for the future will be to delineate which combination of integrin-mediated signaling, cytokine activation and cytoskeletal rearrangements is causative for the CAM-DR phenotype.
Summary
In conclusion, there exists substantial evidence that the tumor microenvironment may contribute to the failure of standard chemotherapy to eradicate the entire tumor population and may facilitate the emergence of acquired drug resistance. The microenvironment is diverse and is most likely disease specific. We have identified FN adhesion as being involved in a form of de novo resistance to both cytotoxic and physiological means of cell death. A multitude of adhesion receptors exist on tumor cells, and thus the challenge for the future will be to determine if CAM-DR represents a redundant survival pathway or if it is specific to b1 inetgrins. If it is indeed a redundant pathway, than the delineation and identification of downstream targets will be critical for reversing the CAM-DR phenotype in vivo.
